| Name | Title | Contact Details |
|---|---|---|
Jinhee Chang |
Intellectual Property Counsel | Profile |
Fred Medick |
General Counsel | Profile |
Aviva Gilbert |
Assistant General Counsel, Senior | Profile |
Yan Qi |
Director and Assistant General Counsel, Platforms | Profile |
Sarah Tully |
Director and Assistant General Counsel | Profile |
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
EMD Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nacalai USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ReproSource is a Bedford, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Santurus is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.